Veterinary evidence · Oxyglobin · HBOC-301

Oxyglobin / HBOC-301 — regulatory approval, clinical efficacy, oxygen delivery & scientific evidence.

Oxyglobin is hemoglobin glutamer-200 (bovine), developed as HBOC-301. This evidence page separates regulatory approval, clinical efficacy, direct comparison with packed red blood cells and oxygen-delivery research from any future BHOC formulation.

The Product Evidence Catalogue contains product-associated Oxyglobin and Hemopure publication records across applications. The figures below describe that catalogue. They include different study designs and are not a count of independent clinical trials.

208Publication recordsUnique records in this application view10Species / model groupsRecorded catalogue groups101Author institutionsIndexed author affiliations99JournalsNormalized journal labels
FDA pivotal efficacy

95% vs 32% treatment success in the efficacy population.

The original FDA field trial enrolled 64 client-owned anaemic dogs: 30 randomized to Oxyglobin and 34 to untreated control. Treatment success meant no additional oxygen-carrying support during the following 24 hours; it was not a survival endpoint.

Efficacy population: 20/21 (95%) Oxyglobin vs 9/28 (32%) control, p≤0.001. Intent-to-treat: 22/30 (73%) vs 10/34 (29%), p≤0.001.

Open the FDA field-trial evidence and 24-hour time course →

EMA cause-stratified efficacy

100% treatment success in two evaluable anaemia strata.

The EMA scientific discussion reports treatment success by cause of anaemia using the same 24-hour efficacy concept: no additional oxygen-carrying support was required during the efficacy window.

Blood-loss anaemia

90% vs 45%

Oxyglobin 90% treatment success vs 45% control.

Haemolytic anaemia

100% vs 9%

Oxyglobin 100% treatment success vs 9% control.

Ineffective erythropoiesis

100% vs 50%

Oxyglobin 100% treatment success vs 50% control.

How to read “100%”: all evaluable Oxyglobin-treated dogs in that cause-of-anaemia stratum met the 24-hour treatment-success endpoint. This is not a 100% survival or cure claim.

Open the detailed EMA / EU treatment-success evidence and source documents →

Prospective randomized clinical comparison · 2009

Oxyglobin vs packed red blood cells in canine babesiosis.

Zambelli AB, Leisewitz AL. Twelve dogs with naturally occurring Babesia rossi anaemia were randomized to Oxyglobin or packed red blood cell transfusion. The study reported similar overall improvements in blood-gas, acid-base and blood-pressure measures, while packed cells tended to normalize habitus and appetite more rapidly.

PMID 19691591 · DOI 10.1111/j.1476-4431.2009.00386.x

PubMed →
Oxygen delivery · British Journal of Anaesthesia · 2001

Intestinal perfusion and oxygenation in canine hypovolaemia.

Driessen B, Jahr JS, Lurie F, Griffey SM, Gunther RA. This British Journal of Anaesthesia paper is a distinct full publication and is now retained separately from the related Veterinary Anaesthesia and Analgesia record.

PMID 11575346 · DOI 10.1093/bja/86.5.683

PubMed →
Metadata correction · feline clinical evidence

44 hypotensive cats — JAVMA citation corrected.

Wehausen CE, Kirby R, Rudloff E. The prior journal label Hb-200 was incorrect. The verified source is the Journal of the American Veterinary Medical Association, 2011;238(7):909-914.

PMID 21453180 · DOI 10.2460/javma.238.7.909

PubMed →
Historical feline Oxyglobin evidence · 2008

Clinical Oxyglobin use in 48 cats.

Weingart C, Kohn B. Retrospective report of 48 anaemic cats treated with Oxyglobin. Interpret adverse events and outcome only in the context of the studied product and clinical population; this is not BHOC-specific evidence.

PMID 18455461 · DOI 10.1016/j.jfms.2007.10.012

PubMed →
Curation note

Similar titles are not automatically duplicate publications.

The British Journal of Anaesthesia paper PMID 11575346 and the related Veterinary Anaesthesia and Analgesia record PMID 28404246 are retained as separate records. The former must not replace the latter.

The historical parasite-induced anaemia record bhoc-056 remains in the bibliography but is explicitly marked SOURCE VERIFICATION REQUIRED until a sufficiently reliable primary PMID or DOI is established.

The live search applies these verified additions and corrections through the curated evidence layer while preserving the original 236-record bibliography snapshot for provenance.

01 / Search

Find the publication.

Search the active evidence layer by species, author, institution, journal, year or topic.

Open publication search →
02 / Base catalogue

Read the source bibliography.

Browse the preserved base catalogue with titles, authors, journals, PubMed records, DOI links and affiliations.

Open full catalogue →
03 / Regulatory

Separate approval from literature.

FDA and EU / EMA records for Oxyglobin remain in the regulatory source library, including primary approval documents.

Open regulatory evidence →

Publication updates →

Library update · 30 October 2026

23 source-linked publication records added

The additions include clinical reports, preclinical studies, analytical methods, reviews and one conference abstract. Twelve are product-associated records and eleven remain in Related Scientific Articles. Publication counts do not represent independent trial counts.

Each record states its study setting and source-review limits. Unconfirmed commercial formulations remain related context. Seven archival citations still require primary documents and were not added as verified publications. Existing records, including Callan and Rentko 2003 and the Zambelli 2009 clinical comparison, were retained without duplication.

Product-associated publications

  1. Effects of chemical modifications on hemoglobin's toxicity towards human cardiac myocytes (2025). Preclinical in vitro cellular study
  2. Hemoglobin-based oxygen carriers: Biochemical, biophysical differences, and safety (2025). Review
  3. Novel high molecular weight polymerized hemoglobin in a non-obese model of cardiovascular and metabolic dysfunction (2024). Preclinical animal study
  4. HBOC-301 in Porcine Kidney Normothermic Machine Perfusion and the Effect of Vitamin C on Methemoglobin Formation (2022). Preclinical ex vivo organ-perfusion study
  5. Transcriptional Suppression of Renal Antioxidant Enzyme Systems in Guinea Pigs Exposed to Polymerized Cell-Free Hemoglobin (2016). Preclinical animal safety study
  6. Investigation of the effects of a polymerised bovine haemoglobin solution on tension in isolated canine saphenous artery (2014). Preclinical ex vivo vascular study
  7. Comparison of Hb-200 and 6% hetastarch 450/0.7 during initial fluid resuscitation of 20 dogs with gastric dilatation-volvulus (2012). Randomized veterinary clinical comparison
  8. Low oxygen-affinity hemoglobin solution increases oxygenation of partially ischemic tissue during acute anemia (2010). Preclinical animal microcirculation study
  9. Glutaraldehyde-polymerized bovine hemoglobin and phosphodiesterase-5 inhibition (2009). Preclinical animal hemodynamic study
  10. The effect of the polymerized bovine haemoglobin solution, Hb-200, on endothelial function in isolated arterial rings from rats (2007). Preclinical ex vivo vascular study
  11. Validation of oxygen saturation measurements in a canine model of hemoglobin-based oxygen carrier infusion (2003). Analytical / monitoring validation study
  12. Low-volume resuscitation with a haemoglobin-based oxygen carrier Hemoglobin glutamer-200 (bovine) in canine hypovolaemia (2001). Conference abstract / experimental model

Related studies, reviews and formulation context

  1. Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023? (2023). Review
  2. Biophysical properties of tense quaternary state polymerized human hemoglobins bracketed between 500 kDa and 0.2 μm in size (2022). Preclinical formulation / laboratory study
  3. Tangential flow filtration facilitated fractionation and PEGylation of low and high-molecular weight polymerized hemoglobins and their biophysical properties (2022). Preclinical formulation / laboratory study
  4. Blood-brain barrier disruption and oxidative stress in guinea pig after systemic exposure to modified cell-free hemoglobin (2011). Preclinical animal safety study
  5. Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide (2011). Preclinical animal study
  6. Isovolemic exchange transfusion with increasing concentrations of low oxygen affinity hemoglobin solution limits oxygen delivery due to vasoconstriction (2008). Preclinical animal study
  7. Multiple red cell transfusions in 27 cats (2003-2006): indications, complications and outcomes (2008). Retrospective veterinary clinical series
  8. Disseminated intravascular coagulation in cats (2006). Retrospective veterinary clinical series
  9. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers (2006). Preclinical animal mechanistic study
  10. Carbon monoxide toxicity: a case series (2005). Veterinary clinical case series
  11. Fetal oxygen content is restored after maternal hemorrhage and fluid replacement with polymerized bovine hemoglobin, but not with hetastarch, in pregnant sheep (2001). Preclinical animal pregnancy model